368 filings
Page 5 of 19
EFFECT
8rcvyqbg
4 May 23
Notice of effectiveness
12:15am
CORRESP
etgro227qlvhesa3bdpd
1 May 23
Correspondence with SEC
12:00am
DEFA14A
r49d9 lyk6x9jh
28 Apr 23
Additional proxy soliciting materials
4:15pm
8-K
ijpzc29
17 Apr 23
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
4:06pm
UPLOAD
9tkhlshicv q5b7x4
17 Apr 23
Letter from SEC
12:00am
4
il8kn7hyov4t9q2xbe
4 Apr 23
Change in insider ownership
4:08pm
8-K
at11cj11yw2y9i40c2b1
30 Mar 23
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
4:07pm
8-K
ktafn1ffeh
8 Mar 23
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
4:10pm
8-K
mabd tzwyjlnq0u
2 Mar 23
Entry into a Material Definitive Agreement
8:05am
SC 13G/A
m4dzpgoadkzopwwd7qq
14 Feb 23
AVENUE THERAPEUTICS / CVI Investments ownership change
11:22am
D
fax21ncy6p36l
14 Feb 23
$242.54 k in options, sold $242.54 k, 1 investor
9:15am
S-8
pnnggn 50
10 Feb 23
Registration of securities for employees
4:06pm
8-K
7gi7wb8z48b7d4uxr
10 Feb 23
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
fb0skurfplv
3 Feb 23
Departure of Directors or Certain Officers
4:05pm
8-K
iffnnstyae1fqc9fs q4
1 Feb 23
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
8:15am
424B5
vh12o bcexkl
31 Jan 23
Prospectus supplement for primary offering
12:05pm
8-K
6ve4r3v0zf1a4axkj
25 Jan 23
Changes in Registrant's Certifying Accountant
4:10pm